Drug Trial Radar · NCT04976322
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
760
Planned (sponsor's estimate)
Start
Jul 27, 2021
Primary completion
Aug 7, 2030
Study completion Aug 7, 2030
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jul 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
Conditions
- Systemic Lupus Erythematosus
Interventions
Dapirolizumab pegolDrug
Subjects will receive dapirolizumab pegol at prespecified time-points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) during the studyTime frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
- Incidence of serious treatment-emergent adverse events during the studyTime frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
- Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuationTime frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Locations
123 sites in 24 countries. Site status is shown where the registry gives one.
Sl0046 50140
Birmingham, Alabama
Sl0046 50058
Avondale, Arizona
Sl0046 50662
Glendale, Arizona
Sl0046 50052
Phoenix, Arizona
Sl0046 50328
Tucson, Arizona
Sl0046 50383
Beverly Hills, California
Sl0046 50275
La Palma, California
Sl0046 50316
San Leandro, California
Sl0046 50339
Denver, Colorado
Sl0046 50239
Brandon, Florida
Sl0046 50362
Gainesville, Florida
Sl0046 50681
Miami, Florida
Sl0046 50059
Ormond Beach, Florida
Sl0046 50324
Plantation, Florida
Sl0046 50329
Tampa, Florida
Sl0046 50698
Tampa, Florida
Sl0046 50368
Atlanta, Georgia
Sl0046 50240
Idaho Falls, Idaho
Sl0046 50699
Chicago, Illinois
Sl0046 50474
Hopkinsville, Kentucky
Sl0046 50285
Lake Charles, Louisiana
Sl0046 50660
New Orleans, Louisiana
Sl0046 50015
Hagerstown, Maryland
Sl0046 50219
Detroit, Michigan
Sl0046 50273
Las Vegas, Nevada
Sl0046 50366
Canton, New York
Sl0046 50264
Manhasset, New York
Sl0046 50334
New York, New York
Sl0046 50238
Charlotte, North Carolina
Sl0046 50147
Hershey, Pennsylvania
Sl0046 50001
Jackson, Tennessee
Sl0046 50738
Bellaire, Texas
Sl0046 50418
Colleyville, Texas
Sl0046 50050
Beckley, West Virginia
Sl0046 60002
Buenos Aires, Argentina
Sl0046 60029
Mendoza, Argentina
Sl0046 60003
Quilmes, Argentina
Sl0046 60022
Quilmes, Argentina
Sl0046 60011
San Juan, Argentina
Sl0046 60014
San Miguel de Tucumán, Argentina
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.